Sun Pharma's Dadra unit had received an Official Action Indicated (OAI) status from the USFDA on April 11 this year. This was after the regulator had inspected the facility between December 4 to December 15, 2023.
Sun Pharma's Dadra unit is involved in the production of oral solid dosage forms and in the manufacturing of the generic Revlimid, which has been a key driver of sales for many pharma companies including Dr. Reddy's, in recent times.
No comments:
Post a Comment